Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9181496 | 0.85 | TERT (0.51) | TERTL3MBTL1HSD17B10TSHRMEN1 | |
| SCHEMBL5014206 | 0.83 | KMT2A (0.48) | TERTHSD17B10TSHRMEN1KMT2A | |
| SCHEMBL1027714 | 0.79 | L3MBTL1 (0.48) | TERTL3MBTL1MEN1KMT2ALMNA | |
| SCHEMBL14142562 | 0.79 | L3MBTL1 (0.47) | TERTL3MBTL1 | |
| SCHEMBL3548187 | 0.79 | L3MBTL1 (0.47) | TERTL3MBTL1 | |
| SCHEMBL26488866 | 0.79 | LTA4H (0.51) | TERTL3MBTL1HSD17B10TSHRMEN1 | |
| Hydrochloric Acid SCHEMBL2674867 | 0.78 | L3MBTL1 (0.46) | TERTL3MBTL1LMNA | |
| Acetic Acid SCHEMBL30329930 | 0.78 | TSHR (0.47) | TERTL3MBTL1HSD17B10TSHRMEN1 | |
| SCHEMBL31326677 | 0.78 | HSD17B10 (0.48) | TERTL3MBTL1HSD17B10TSHRMEN1 | |
| SCHEMBL5009345 | 0.77 | MAPK1 (0.41) | TERTL3MBTL1HSD17B10TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748422-B2 | Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-06-10 | — | — | US | claimed |
| US-20090054433-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-02-26 | — | — | US | claimed |
| US-8748422-B2 | Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-06-10 | — | — | US | disclosed |
| US-20090054433-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-02-26 | — | — | US | disclosed |
| WO-2008007835-A1 | 2,4-QUINAZOLINE DERIVATIVES HAVING ACTIVITY TO T-TYPE CALCIUM CHANNEL AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054433-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST | HTR3A, HTR3B, HTR3E | TERT 4780/4885L3MBTL1 4448/4885HSD17B10 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.